Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNMBiotechnology
-$0.39 today
- Market cap
- $326.66M
- Beta
- 0.89
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$1.57
Volume 0.20M
Average 0.26M
CTNM Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Contineum Therapeutics, Inc. Class A Common StockNASDAQ: CTNM
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income dips below year-ago levels
Q1 FY2026 net income of $14.46M (cash outflow) fell 9.6% year over year, behind the +17.3% change in trailing-twelve-month net income. Sequentially, it fell 4.6% from the prior quarter. Over 3 fiscal years it compounded at +35.2% a year.
Context
- Net income increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$49.45M (-17.6%) for the fiscal year ending Dec 2026, a slowdown from the +41.9% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$14.46M-4.6% QoQ
- Last fiscal yearDec 2025
- -$59.98M+41.9% YoY
- LTMMar 2026
- -$58.44M+17.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -9.6% | +4.8% | +14.4 pp |
| 1 year | +41.9% | -17.6% | -59.5 pp |
| 3-year CAGR | +35.2% | -2.2% | -37.4 pp |
| 5-year CAGR | +3.3% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (59.98M) USD
- Year-over-year change
- -41.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (59.98M) | -41.9% |
| FY2024 | 2024-12-31 | (42.26M) | -286.0% |
| FY2023 | 2023-12-31 | 22.72M | +193.7% |
| FY2022 | 2022-12-31 | (24.25M) | +16.4% |
| FY2021 | 2021-12-31 | (29M) | — |
Net Income vs competitors
How CTNM compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +17.3% is the 6th highest of 7, against a peer median of +34.3%.
- Over three fiscal years its annual growth of +35.2% compares with a peer median of +29.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $222.39M USD | -13.8% | +21.9% | — |
| LTM Mar 2026 | $199.48M USD | +146.3% | +75.1% | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $107.28M USD | +34.6% | +118.7% | 536.4% |
| LTM Mar 2026 | $74.31M USD | +17.6% | +31.7% | — | |
| LTM Dec 2025 | CHF 70.34M CHF | +38.1% | -1.7% | 1968.6% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $58.44M USD | +17.3% | +35.2% | — |
| LTM Mar 2026 | $56.41M USD | +34.0% | +29.0% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $39.17M USD | — | +20.7% | — |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding CTNM) | — | +34.3% | +29.0% | 1252.5% | |
Competitors are the stored peer set for CTNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (29M) | (24.25M) | 22.72M | (42.26M) | (59.98M) |
| Depreciation & Amortization | 325K | 329K | 195K | 258K | 323K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.75M | 1.93M | 2.22M | 6.8M | 10.04M |
| Change in Working Capital | 108K | (1.27M) | (1.02M) | 5.33M | (6.04M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (110K) | (230K) | 0 | 1.14M | (869K) |
| Other Working Capital | 218K | (1.04M) | (1.02M) | 4.19M | (5.17M) |
| Other Non-Cash Items | 553K | 3.14M | (4.76M) | (2.98M) | 344K |
| Operating Cash Flow | (26.27M) | (20.12M) | 19.35M | (32.85M) | (55.31M) |
| Capital Expenditures | (168K) | (118K) | (414K) | (514K) | (231K) |
| Acquisitions (Net) | 0 | 0 | 0 | 20K | 0 |
| Purchases of Investments | (66.78M) | (64.7M) | (141.87M) | (226.41M) | (162.5M) |
| Sales of Investments | 1.98M | 87.12M | 76.71M | 157.16M | 159.02M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (64.97M) | 22.3M | (65.57M) | (69.74M) | (3.71M) |
| Debt Repayment | 0 | (1.25M) | (3.75M) | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 108.21M | 112.69M |
| Common Stock Repurchased | 0 | (4K) | (28K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 113K | 15K | (184K) | 790K | 0 |
| Financing Cash Flow | 79.84M | (1.24M) | 56.18M | 109M | 112.69M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (11.4M) | 939K | 9.96M | 6.42M | 53.66M |
| Free Cash Flow | (26.43M) | (20.24M) | 18.94M | (33.36M) | (55.54M) |
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
Intrinsic Alpha fair value
Locked
Current Price
$9.24
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.